Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

229
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

238
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
238
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

276
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
276
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

200
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
200
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

312
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
312

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seizure relapse in new onset epilepsy: It is not always drug resistance.

Epilepsia·2026
Same author

Scalp-negative medial temporal interictal epileptic discharges alter large-scale brain networks: A simultaneous high-density electroencephalographic and intracranial electroencephalographic study.

Epilepsia·2025
Same author

An optimized framework for simultaneous EEG-fMRI at 7T enabling safe, high-quality human brain imaging with millisecond temporal resolution and sub-millimeter spatial resolution.

Imaging neuroscience (Cambridge, Mass.)·2025
Same author

EEG focal delta slowing in focal epilepsy - A didactic review.

Clinical neurophysiology practice·2025
Same author

High-Density EEG Source Localisation of averaged interictal epileptic Discharges validated by surgical Outcome.

Scientific data·2025
Same author

Emergent technologies in clinical neurophysiology to study the central nervous system: IFCN handbook chapter.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2025

Related Experiment Video

Updated: Jan 25, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.7K

[Comorbidities: which drug for which patient ?]

Noëlle Mercier1, Serge Vulliémoz2

  • 1Epileptologie et médecine du handicap, Institution de Lavigny, route du Vignoble 60, 1175 Lavigny.

Revue Medicale Suisse
|April 26, 2019
PubMed
Summary

New antiepileptic drugs (AEDs) offer better tolerability and fewer interactions than older options. Individualized treatment selection remains crucial, as optimal choices depend on patient-specific factors beyond current evidence-based guidelines.

More Related Videos

Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
09:50

Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish

Published on: April 10, 2020

8.7K
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.0K

Related Experiment Videos

Last Updated: Jan 25, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.7K
Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
09:50

Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish

Published on: April 10, 2020

8.7K
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.0K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Medicine

Background:

  • Established antiepileptic drugs (AEDs) have varying efficacy and side effect profiles.
  • Newer AEDs present improved tolerability and reduced drug-drug interaction potential.
  • Current evidence-based guidelines do not definitively identify the optimal AED for all patients.

Purpose of the Study:

  • To review the comparative efficacy and tolerability of new versus older antiepileptic drugs.
  • To outline key principles and factors for individualized AED selection.
  • To guide clinicians in tailoring epilepsy treatment strategies.

Main Methods:

  • Review of current literature on antiepileptic drug efficacy and safety.
  • Analysis of drug interaction profiles for older and newer AEDs.
  • Synthesis of clinical factors influencing AED choice.

Main Results:

  • Newer AEDs demonstrate comparable efficacy to older agents.
  • Newer AEDs exhibit significantly better tolerability and fewer drug interactions.
  • Evidence-based medicine lacks definitive guidance for personalized AED selection.

Conclusions:

  • Individualized patient assessment is paramount for optimal epilepsy management.
  • Treatment decisions should consider tolerability, drug interactions, and patient-specific factors.
  • A tailored approach is necessary due to the limitations of current guidelines in selecting the best AED.